

Electronic Acknowledgement Receipt

EFS ID:	3850929
Application Number:	09868123
International Application Number:	
Confirmation Number:	5639
Title of Invention:	Cytokine receptor chain
First Named Inventor/Applicant Name:	Mary Collins
Correspondence Address:	Mintz Levin Cohn Ferris Glovsky and Popeo - One financial Center - Boston MA 02111 US - -
Filer:	Diana Collazo
Filer Authorized By:	
Attorney Docket Number:	22058-514NATL
Receipt Date:	27-AUG-2008
Filing Date:	02-APR-2002
Time Stamp:	18:27:57
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180

RAM confirmation Number	5360				
Deposit Account	502762				
Authorized User					
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)</p>					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	W2023_7013US_SB08a_2.PDF	640850 4065a463a60071de4d98668c8fa5b0ecd1e0de5a	no	7
Warnings:					
Information:					
<p>A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.</p>					
2	NPL Documents	W2023_7013US_AppealBriefby UCB.PDF	622694 a3ce9602c12747c7760cc9eefaa250d574da8c74	no	12
Warnings:					
Information:					
3	NPL Documents	W2023_7013US_AppealBriefby AstraZenecaAB.PDF	1030967 7c649fb751c56e419b8f5deeccebb4f35738f328	no	19
Warnings:					
Information:					
4	NPL Documents	W2023_7013US_AppealBriefby GlaxoGroup.PDF	2287504 5eed8f5f550daa770210d419b1374665c0683309	no	46
Warnings:					
Information:					
5	NPL Documents	W2023_7013US_Oppositionrec eivedbyEPoffice.PDF	1005176 598db80bc061675a2ff1bb09bb7e2b966e936a58	no	19
Warnings:					
Information:					
6	NPL Documents	W2023_7013US_IntlSearchRpt PCTUS9929493.PDF	107765 43e7d165f1e2c78e2dd0a7d40b440d2b8e59665c	no	3
Warnings:					

Information:					
7	NPL Documents	W2023_7013US_IntlSearchRpt PCTUS0521454.PDF	139190	no	3
			300f94bbb83fb13f908bafda5617ab9314423c57		
Warnings:					
Information:					
8	NPL Documents	W2023_7013US_IntlSearchRpt PCTUS2007025418.PDF	327410	no	7
			9f68827259f77c328d846228e8423098a638aa7b		
Warnings:					
Information:					
9	NPL Documents	W2023_7013US_IL13blockader educslung.PDF	797431	no	7
			635f5695365d059ecd351e4ce9a0b29c9d21231		
Warnings:					
Information:					
10	NPL Documents	W2023_7013US_PreclinicalPha rmacokinetics.PDF	1823540	no	15
			d8406cdabfc6d33747830554fb54693c0ef3738e		
Warnings:					
Information:					
11	NPL Documents	W2023_7013US_IL13Signaling ThroughtheIL13x2.PDF	826460	no	8
			d322cc610565624f895170992af931fc53dd5582		
Warnings:					
Information:					
12	NPL Documents	W2023_7013US_EfficacyofIL13 Neutralization.PDF	1005765	no	9
			d6041fc76d9272942827126604cc3cd067e2d0c1		
Warnings:					
Information:					
13	NPL Documents	W2023_7013US_KineticAnalysi softheInterleukin13.PDF	695055	no	6
			f391df91baa30c1b797fb75572ce07f7df2de73c		
Warnings:					
Information:					
14	NPL Documents	W2023_7013US_ExpressionofIL 12andIL13mRNAin.PDF	1112287	no	8
			2c5552aa987110ff4468632f85b1dbc979b6ff39		
Warnings:					
Information:					
15	NPL Documents	W2023_7013US_NasalMastCell sinPerennial.PDF	787326	no	8
			80e5c76334de32807070a5f81b03ef2e7aa53999		
Warnings:					

Information:					
16	NPL Documents	W2023_7013US_GeneticSusceptibilitytoAsthma.PDF	704230	no	7
			f38483d4d4cc497fb9f7f2ba7bda04c6e26958dd		
Warnings:					
Information:					
17	NPL Documents	W2023_7013US_CytokinesandILgERegulation.PDF	2208360	no	28
			52a75f91668cb85ac47038bd1c66b19f4146c072		
Warnings:					
Information:					
18	NPL Documents	W2023_7013US_IL13InducedAirway.PDF	891816	no	7
			6877d1eb9bae38cd48176087cc23f8056b127643		
Warnings:					
Information:					
19	NPL Documents	W2023_7013US_NKTcellmediated.PDF	687712	no	6
			dlcfb6043e7e480885c850de2c1b9cf28d9fc8561		
Warnings:					
Information:					
20	NPL Documents	W2023_7013US_AMurinelL4Receptor.PDF	1057784	no	9
			c82ff585aa6927861e1a6483f03d46ea27465306		
Warnings:					
Information:					
21	NPL Documents	W2023_7013US_IL13MediatedWorm.PDF	729288	no	7
			d58313ee39a5ed93fe05386956d4bb4f6b56c395		
Warnings:					
Information:					
22	NPL Documents	W2023_7013US_TheroleofIL13.PDF	619638	no	7
			955e1e752865fce338d9f1190193c42be0f0a12d		
Warnings:					
Information:					
23	NPL Documents	W2023_7013US_Interleukin13sKeyRole.PDF	292593	no	2
			fa5a58a278d7932da0caf406d4e7d86f5b1b2d02		
Warnings:					
Information:					
24	NPL Documents	W2023_7013US_CriticalRoleforIL13inthe.PDF	987391	no	8
			1e3b4f08a2591c20c2de40353bb6c7eb4999a32f		
Warnings:					

Information:					
25	NPL Documents	W2023_7013US_Bronchialhyperresponsiveness.PDF	494215	no	5
			65713540ab20cb2793517edf69ab9ad25205288c		
Warnings:					
Information:					
26	NPL Documents	W2023_7013US_PolymorphismsNotFound.PDF	165888	no	2
			3ba5d57ac7db189d14c7f4b64596044acb76e602		
Warnings:					
Information:					
27	NPL Documents	W2023_7013US_Interleukin13CentralMediator.PDF	609736	no	5
			8b1b71ddcd33c23d416d26a9e2387194d6cd5901		
Warnings:					
Information:					
28	NPL Documents	W2023_7013US_TheroleofIgEinasthma.PDF	575093	no	7
			e606b1c135c844726e3277098f822a3f41b71de6		
Warnings:					
Information:					
29	NPL Documents	W2023_7013US_Receptorsforinterleukin13and.PDF	732541	no	8
			24dadadd51b13e93a6c1d3f28ae73d61155f3b71		
Warnings:					
Information:					
30	NPL Documents	W2023_7013US_ThePrimaryBindingSubunitof.PDF	981308	no	10
			6504d471c5c42eedee202c583c1db3c6aa0bbdf7		
Warnings:					
Information:					
31	NPL Documents	W2023_7013US_RequirementforIL13IndependentlyofIL4.PDF	479545	no	3
			0133677fb9ad733494261416f2ff51a789407114		
Warnings:					
Information:					
32	NPL Documents	W2023_7013US_AppealBriefbyGenentech.PDF	740653	no	13
			423dc5da5d6cce944f9e046f13d03c950171ac22		
Warnings:					
Information:					
33	NPL Documents	W2023_7013US_AppealBriefbySchlich.PDF	395670	no	12
			934c3dcfb0b85d5a8853713f9711aa82b4246c68		
Warnings:					

Information:					
34	Fee Worksheet (PTO-06)	fee-info.pdf	30215	no	2
			10812f88bd33e88de1a3eae8b2b05d113a967778		
Warnings:					
Information:					
			Total Files Size (in bytes):	26593096	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					